Anti-LC3-I/II Antibody

Autophagy assay cell type - Mino

Experiment
Autophagy assay cell type - Mino
Product
Anti-LC3-I/II Antibody from Sigma-Aldrich
Manufacturer
Sigma-Aldrich

Protocol tips

Protocol tips
-Add primary Ab and incubate with agitation for 1 hour.

Publication protocol

Immunoblots were performed as described previously.14 Abs to the following proteins were used: actin and CD74 (Santa Cruz Biotechnology); microtubule-associated protein 1 light chain 3 (LC3) and Beclin-1 (Sigma-Aldrich); and p62/SQSTM1 (Medical & Biological Laboratories). Further details are available in supplemental Methods (available on the Blood Web site; see the Supplemental Materials link at the top of the online article).

Full paper   Login or join for free to view the full paper.

Reviews

Anti-LC3-I/II Antibody from Sigma-Aldrich has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Autophagy assay cell type - Mino using Anti-LC3-I/II Antibody from Sigma-Aldrich.

Paper title
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death
Full paper
Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Sigma-Aldrich for Anti-LC3-I/II Antibody below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Autophagy assay cell type - Mino using Anti-LC3-I/II Antibody from Sigma-Aldrich. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms